Developer of nano medicines designed to develop a new generation of replacement therapies for rare diseases. The company's medicines include orphan drugs that combine replacement therapies - substrates, enzymes, or proteins - with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs, enabling physicians treat their patients with for serious rare monogenic disorders of metabolism and protein misfolding.